Related Experiment Video
Updated: Jul 7, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
The role of angiogenesis inhibitors in prostate cancer
Jeanny B Aragon-Ching1, William L Dahut
1Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Prostate cancer is the leading noncutaneous malignancy in American men. Only the combination of docetaxel and prednisone has been shown to improve survival in patients with metastatic castrate-resistant prostate cancer. However, responses are short and a search for better agents either alone or synergistic with chemotherapy continues to be an urgent medical need. Angiogenesis has been shown to be a prerequisite event for tumor growth and metastasis in prostate cancer. Several strategies have been used to target angiogenesis in prostate cancer. These include blocking of pro-angiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, direct inhibition of endothelial cells, or targeting other receptors involved in cell adhesion, proliferation, and survival. Agents such as thalidomide and bevacizumab have shown encouraging results in phase II trials, and this review focuses on the clinical trials that have used these agents and other novel agents. The use of angiogenesis inhibitors is rapidly emerging as a promising treatment strategy in a variety of solid tumors, currently including prostate cancer.
Insights
New angiogenesis inhibitors offer hope for metastatic castrate-resistant prostate cancer. These agents target tumor blood vessel growth, addressing an urgent need for improved treatments beyond current chemotherapy options.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Prostate cancer is a leading malignancy in men.
- Metastatic castrate-resistant prostate cancer (mCRPC) has limited treatment options, with docetaxel and prednisone offering short-lived survival benefits.
- Angiogenesis is crucial for prostate cancer growth and metastasis, creating a therapeutic target.
Purpose of the Study:
- To review clinical trials of novel angiogenesis inhibitors for prostate cancer.
- To explore agents targeting tumor angiogenesis as a treatment strategy for mCRPC.
- To identify promising new therapies for prostate cancer beyond conventional chemotherapy.
Main Methods:
- Review of clinical trials involving angiogenesis inhibitors in prostate cancer.
- Analysis of strategies targeting angiogenesis, including monoclonal antibodies and small molecule inhibitors.
- Focus on agents like thalidomide and bevacizumab in phase II trials.
Main Results:
- Angiogenesis inhibitors are emerging as a promising treatment strategy for solid tumors, including prostate cancer.
- Agents like thalidomide and bevacizumab have shown encouraging results in phase II trials for prostate cancer.
- Novel agents are being investigated for monotherapy or synergistic use with chemotherapy in mCRPC.
Conclusions:
- Targeting angiogenesis represents a significant advancement in prostate cancer treatment.
- Further clinical trials are warranted to establish the efficacy and safety of novel angiogenesis inhibitors.
- Angiogenesis inhibition holds promise for improving outcomes in patients with advanced prostate cancer.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
02:34Inhibition of Cdk Activity